Teladoc Health (TDOC) Fundamental Analysis: Revenue, Earnings & Valuation

0.82 / 10

Underperform

Fundamental analysis rates Teladoc as Underperform with a 0.82/10 score. Asset‑MV and liquidity ratios score modestly, while profit‑to‑market and net‑income metrics are weak. Overall financial health is constrained, suggesting limited upside.

Analysis Checks(5/10)

Profit-MV

Value0.68

Score1/3

Weight19.70%

1M Return-3.58%

Net income-Revenue

Value-0.04

Score1/3

Weight23.92%

1M Return-4.57%

Quick ratio

Value2.67

Score1/3

Weight14.65%

1M Return-2.25%

Rate of return on total assets (%)

Value-7.92

Score2/3

Weight3.52%

1M Return-0.49%

Fixed assets turnover ratio

Value46.14

Score0/3

Weight38.02%

1M Return-6.24%

Long-term debt to working capital ratio (%)

Value1.49

Score0/3

Weight28.92%

1M Return-4.40%

Annualized return on total assets (%)

Value-7.92

Score2/3

Weight3.52%

1M Return-0.49%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight12.58%

1M Return-1.91%

Asset-MV

Value-0.48

Score2/3

Weight-61.41%

1M Return8.15%

Current assets / Total assets (%)

Value39.15

Score2/3

Weight16.58%

1M Return-2.61%

Is TDOC undervalued or overvalued?

TDOC scores 0.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -13.93% ROE, -7.92% net margin, -4.83 P/E ratio, 0.70 P/B ratio, and 80.58% earnings growth, these metrics solidify its Underperform investment rating.